CTL responses to human papillomavirus oncoproteins

Hepatitis B surface antigen fusions delivered by DNA vaccination elicit CTL
responses to human papillomavirus oncoproteins associated with tumor protection








We describe the construction and evaluation of a recombinant hepatitis B
surface antigen (HBsAg)-vectored DNA vaccine encoding the E7 and E6 tumor-
associated oncoproteins of human papillomavirus (HPV) type 16. We show
the induction of effector and memory cytotoxic T lymphocyte responses to E7
and E6 class I-restricted epitopes after a single immunization, which were
associated with tumor prevention and therapy. The findings vindicate the use of
a HBsAg-based DNA vaccine as a vehicle to elicit responses to co-encoded tumor
antigens, and have specific implications for the development of a therapeutic
vaccine for HPV-associated squamous carcinomas.




Cancer Gene Therapy 17, 708-720 (October 2010) |
doi:10.1038/cgt.2010.27